Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2026Journal of Clinical Psychopharmacology

An Open-Label, Randomized, Active Controlled Trial Evaluating Sublingual Dexmedetomidine for Moderate to Severe Agitation in Inpatients With Schizophrenia or Bipolar Disorder

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates sublingual dexmedetomidine's efficacy for agitation in inpatients, indicating promise for treatment.

Key Points

  • This study aimed to assess the efficacy of sublingual dexmedetomidine in treating acute agitation among inpatients with schizophrenia or bipolar disorder.
  • Pragmatic, randomized, open-label, active-controlled trial
  • Participants diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder randomization to dexmedetomidine or lorazepam
  • Primary endpoint was change in PANSS-EC score at 2 hours post-medication administration.
  • At 2 hours, PANSS-EC score change for dexmedetomidine was -13.0 (IQR -17.0 to -10.0)
  • PANSS-EC score change for lorazepam was -14.0 (IQR -19.0 to -12.0)
  • No spontaneously reported adverse effects were observed in either treatment group.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a7d75f62b0e0cff3f63ee8ahttps://doi.org/10.1097/jcp.0000000000002232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Severe hypotension following sublingual dexmedetomidine administration in an elderly patient2025
  2. 2Dexmedetomidine versus No-sedation for Agitation Control in COPD Patients receiving Noninvasive Ventilation: a Randomized Trial2026
  3. 3Dexmedetomidine Continuous Infusion to Maintain Sedation in Severely Agitated Adolescents in the Emergency Department2026 · 1 citations
  4. 4Sublingual dexmedetomidine: An old drug with a new route for agitation2025
  5. 5Clinical Experience With Dexmedetomidine for Postictal Agitation After Electroconvulsive Therapy2026